Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

• Status: Completed
• Trial end date: 2020-01-09
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to compare total opioid consumption by subjects in different treatment groups.

Another purpose of this study is to assess how well EXPAREL works, collect any safety data and assess your satisfaction using EXPAREL.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pacira Pharmaceuticals, Inc
• Treatments: Morphine

Criteria

Inclusion Criteria:

1. Females 18 years of age and older at screening.

2. Term pregnancies of 37 to 42 weeks gestation, scheduled to undergo elective C-section.

3. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.

4. Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.

Exclusion Criteria:

1. Subjects who, in the opinion of the study site principal investigator, have a high-risk pregnancy.

2. Subjects with a pregnancy-induced medical condition or complication.

3. Subjects with 3 or more prior C-sections.

4. Pre-pregnancy body mass index >50 kg/m2.

5. Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications.

6. Planned concurrent surgical procedure with the exception of salpingo-oophorectomy or tubal ligation.

7. Severely impaired renal or hepatic function.

8. Subjects at an increased risk for bleeding or a coagulation disorder.

9. Concurrent painful physical condition that may require analgesic treatment in the postsurgical period for pain that is not strictly related to the surgery.

10. Clinically significant medical disease in either the mother or baby that, in the opinion of the investigator, would make participation in a clinical study inappropriate.

11. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.

12. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug.

13. Previous participation in an EXPAREL study.

14. Any clinically significant event or condition uncovered during the surgery that might render the subject medically unstable or complicate the subject's postsurgical course.

15. Receives the epidural component of combined spinal epidural (CSE) anesthesia during the study.